Overview

Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

Status:
Recruiting
Trial end date:
2024-01-30
Target enrollment:
Participant gender:
Summary
Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder (MDD) in subjects who have suicidal ideation with intent
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals